Evidence map›Paper›PMID 29067481›Full record

ReviewEuropean journal of clinical pharmacology2018

Are some people at increased risk of paracetamol-induced liver injury? A critical review of the literature.

Thomas M Caparrotta, Daniel J Antoine, James W Dear

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in European journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03648658 (Pharmacokinetics and Safety of Treatment With Paracetamol in Children and Adults With Spinal Muscular Atrophy and Cerebral Palsy), which is not on this map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03648658 phase4unknown statusnot on this mapstarted 2019, after this paper: background citation

Pharmacokinetics and Safety of Treatment With Paracetamol in Children and Adults With Spinal Muscular Atrophy and Cerebral Palsy

TypeinterventionalSponsorMette Cathrine OerngreenRan2019 to 2024Enrolled48ConditionsSMA II, Cerebral PalsyArmsParacetamol 120Mg/5mL Oral Suspension
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 94 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. [Interactions between common drug metabolism and precautions for drug usage in Gilbert syndrome].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Therapeutic liver cell transplantation to treat murine PKU.Journal of inherited metabolic disease · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Solid Organ Transplant Litigation at One of Europe's Largest University Hospitals.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Article
  18. Article
  19. Article
  20. LateClinical case reports · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Thomas M CaparrottaSpeciality Registrar Clinical Pharmacology and Therapeutics, NHS Lothian, Edinburgh, UK.
Daniel J AntoineMRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.
James W DearUniversity/BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK. james.dear@ed.ac.uk.
Centre for Inflammation Research · GBNHS Lothian · GBUniversity of Edinburgh · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeParacetamol is one of the world's most commonly used drugs. In overdose, it is well established to be hepatotoxic. The aim of this review was to identify factors that have been, or actually are, associated with the development of liver injury after paracetamol exposure in humans.

methodGoogle Scholar and PubMed were searched on various dates between December 2016 and March 2017. Papers identified had their references analysed for further studies that might be relevant.

resultsAt the time of writing, there was little good quality clinical evidence-from studies of paracetamol overdose or therapeutic use-to suggest that any groups of people are relatively protected from, or are at greater risk of, liver injury. The factors that were historically used to indicate higher risk in the UK have no good quality clinical evidence to support their re-introduction into clinical practice. The safe (and still effective) oral dose of paracetamol in patients weighing less than 50 kg has not been established.

conclusionThere is no patient group that is unequivocally at elevated risk of paracetamol-induced liver toxicity. We propose two clinical scenarios that warrant further research. Firstly, there is a need to establish whether the dose of paracetamol should be reduced in patients with low body weight. Secondly, if or when genomic information regarding individual patients becomes readily available to inform prescribing, we propose the contribution of the genome to paracetamol toxicity should be re-investigated with robustly designed studies. Such studies could enhance the safe use of one of the most frequently taken drugs.

Indexed as

AcetaminophenAnalgesics, Non-NarcoticChemical and Drug Induced Liver InjuryHumansRisk FactorsAcetaminophenAnalgesics, Non-NarcoticAcetaminophenDILIGenomicsHepatotoxicityParacetamol

Identifiers

PMID29067481
PMCPMC5765191
OpenAlexW2766458512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.